Affibody AB appoints Dr. Ulf Boberg as Chief Executive Officer
Affibody AB announced that Dr. Ulf Boberg has been appointed Chief Executive Officer as from June 1, 2006.
Dr. Ulf Boberg, who joined Affibody in January 2006 as Senior Vice President Development, replaces Dr. Carl-Johan Dalsgaard who as been acting Chief Executive Officer of Affibody since December 2005. Dr. Dalsgaard is a partner of Affibody's largest shareholder HealthCap and will remain a non-executive board member of Affibody. Dr. Boberg holds a PhD in medical science, an MBA from Uppsala University and has 18 years experience from the pharmaceutical and biotechnology industry. Most recently, Dr. Boberg was CEO of Global Genomics AB. Before that, he held the senior roles of vice president and head of the Development Division at Astra Pain Control, leading a team of 170 people, and vice president and R&D site general manager at AstraZeneca. In 2000, Dr. Boberg left AstraZeneca to become investment manager at LinkMed AB. Earlier in his career, he held positions including Head of Medical Research at Gambro, CEO of PMC Clinical Research AB and CEO of Alfta Rehab Center.
Organizations
Other news from the department people

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.